According to a report by Religare Institutional Research “The Indian Pharmaceutical Market (IPM) reported moderate revenue growth of 12 percent y-o-y in February 2016 as against 18.9 percent in February 2015, primarily attributable to steady volumes, sustained healthy price hikes and new launches.”

It further said that therapy-wise, the anti-diabetic, cardiac, derma and gastrointestinal segments outperformed IPM growth by 4-6 percent. The respiratory and anti-infective segments were laggards.

Read EquityPandit’s Nifty Pharma Outlook for this week